<DOC>
	<DOCNO>NCT01137981</DOCNO>
	<brief_summary>The APR begin 'Zidovudine pregnancy Registry ' January 1989 become 'Antiretroviral Pregnancy Registry ' January , 1993 . The purpose APR detect major teratogenic effect involve Registry drug administer pregnant HIV positive woman . The Registry intend provide early signal teratogenicity associate prenatal use antiretroviral drug . The Registry collect data prenatal exposures antiretroviral drug , potential confounding factor ( maternal age , disease status pregnancy ) , information outcome pregnancy . The Registry manage INC Research . The scientific conduct analysis Registry data overseen independent Advisory Committee consist member Centers Disease Control Prevention ( CDC ) , Food Drug Administration ( FDA ) , National Institutes Health ( NIH ) , academic sector . Registry data obtain participate provider encompass physician private practice well hospital community clinic . The registry co-sponsored co-funded 26 pharmaceutical company manufacture drug use ART . For updated version registry , please see NCT00404989 .</brief_summary>
	<brief_title>Antiretroviral Pregnancy Registry ( APR ) -Risk Birth Defects</brief_title>
	<detailed_description>The Registry conforms FDA Guidance Industry : Establishing Pregnancy Exposure Registries , Guidelines Good Pharmacoepidemiology Practices , FDA Guidance Pharmacovigilance . The Antiretroviral Pregnancy Registry collect data use follow GSK drug : abacavir , amprenavir , delavirdine , fosamprenavir , lamivudine , maraviroc , zidovudine , combination pregnancy . The Registry request information medical provider antiretroviral therapy , though may drug exposure , systematically collect . Registration voluntary . Health professional strongly encourage enroll antiretroviral-exposed pregnant patient Registry early pregnancy possible , preferably prenatal test do . This maximize data validity minimize potential bias introduce woman enrol prenatal testing . Patients follow health care provider provide information maternal risk factor , pregnancy outcome , neonatal health . In month expect delivery , short follow-up form send health care provider ascertain pregnancy outcome completion antiviral therapy information . Additional follow-up seek health care provider . In attempt limit bias analysis , Registry assemble group provider commit write report every woman receive antiretroviral therapy pregnancy , pregnancy outcome know , come site . This allow Registry include every report site evaluable case . As number case sit increase , Registry able analyze case separately . Providers encourage participate group . ViiV Healthcare new sponsor study , GlaxoSmithKline process update system reflect change sponsorship .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<mesh_term>Delavirdine</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<criteria>Any pregnant , HIV positive woman expose antiretroviral drug pregnancy .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Combivir ( Zidovudine+Lamivudine )</keyword>
	<keyword>Antiretrovirals</keyword>
	<keyword>ARV</keyword>
	<keyword>HAART</keyword>
	<keyword>Maraviroc</keyword>
	<keyword>Delavirdine</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Antiretroviral Pregnancy Registry</keyword>
	<keyword>Fosamprenavir</keyword>
	<keyword>APR</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>pregnancy registry</keyword>
	<keyword>Amprenavir</keyword>
	<keyword>HIV</keyword>
	<keyword>Trizivir ( Abacavir+Lamivudine+Zidovudine )</keyword>
	<keyword>Epzicom ( Abacavir+Lamivudine )</keyword>
</DOC>